2022
Anti-SARS-CoV-2 and Autoantibody Profiling of a COVID-19 Patient With Subacute Psychosis Who Remitted After Treatment With Intravenous Immunoglobulin
McAlpine L, Lifland B, Check J, Angarita G, Ngo T, Chen P, Dandekar R, Alvarenga B, Browne W, Pleasure S, Wilson M, Spudich S, Farhadian S, Bartley C. Anti-SARS-CoV-2 and Autoantibody Profiling of a COVID-19 Patient With Subacute Psychosis Who Remitted After Treatment With Intravenous Immunoglobulin. Biological Psychiatry 2022, 93: e25-e29. PMID: 36481066, PMCID: PMC9722219, DOI: 10.1016/j.biopsych.2022.09.007.Peer-Reviewed Original Research
2021
Prior Stroke and Age Predict Acute Ischemic Stroke Among Hospitalized COVID-19 Patients: A Derivation and Validation Study
Peng TJ, Jasne AS, Simonov M, Abdelhakim S, Kone G, Cheng YK, Rethana M, Tarasaria K, Herman AL, Baker AD, Yaghi S, Frontera JA, Sansing LH, Falcone GJ, Spudich S, Schindler J, Sheth KN, Sharma R. Prior Stroke and Age Predict Acute Ischemic Stroke Among Hospitalized COVID-19 Patients: A Derivation and Validation Study. Frontiers In Neurology 2021, 12: 741044. PMID: 34675873, PMCID: PMC8524436, DOI: 10.3389/fneur.2021.741044.Peer-Reviewed Original ResearchAcute ischemic strokeHospitalized COVID-19 patientsCOVID-19 patientsCOVID-19 cohortNeurologic symptomsPrior strokeIschemic strokeAIS patientsDerivation cohortControl cohortRisk of AISMultivariable logistic regression modelIschemic stroke riskCOVID-19 severityYale New Haven HealthLogistic regression modelsHospital presentationIndependent predictorsStroke riskMajor health systemsHigh riskPatientsYounger ageCohortStrokeLow-Field, Portable Magnetic Resonance Imaging at the Bedside to Assess Brain Injury in Patients with Severe COVID-19 (1349)
Mazurek M, Yuen M, Cahn B, Rosen M, Gobeske K, Gilmore E, Hwang D, Kaddouh F, Kim J, Falcone G, Petersen N, Siner J, Spudich S, Sze G, Kimberly W, Sheth K. Low-Field, Portable Magnetic Resonance Imaging at the Bedside to Assess Brain Injury in Patients with Severe COVID-19 (1349). Neurology 2021, 96 DOI: 10.1212/wnl.96.15_supplement.1349.Peer-Reviewed Original Research
2020
Coronavirus disease 2019 and neurodegenerative disease: what will the future bring?
McAlpine LS, Fesharaki-Zadeh A, Spudich S. Coronavirus disease 2019 and neurodegenerative disease: what will the future bring? Current Opinion In Psychiatry 2020, 34: 177-185. PMID: 33395100, PMCID: PMC7924921, DOI: 10.1097/yco.0000000000000688.Peer-Reviewed Original ResearchConceptsCoronavirus disease 2019Multiple sclerosisParkinson's diseaseNeurodegenerative diseasesAlzheimer's diseaseDisease 2019High riskCOVID-19Heart/lung diseaseHigh-risk comorbid conditionsHospitalized COVID-19 patientsAltered mental statusCOVID-19 patientsMS patientsSuch patientsComorbid conditionsNeurological symptomsPoor outcomeLung diseaseMental statusAdvanced ageSevere diseasePatientsBetter outcomesViral infection
2014
Treatment of HIV in the CNS: Effects of Antiretroviral Therapy and the Promise of Non-Antiretroviral Therapeutics
Peluso MJ, Spudich S. Treatment of HIV in the CNS: Effects of Antiretroviral Therapy and the Promise of Non-Antiretroviral Therapeutics. Current HIV/AIDS Reports 2014, 11: 353-362. PMID: 25063356, DOI: 10.1007/s11904-014-0223-y.Peer-Reviewed Original ResearchConceptsCentral nervous systemAntiretroviral therapyNew neurologic abnormalitiesTrajectory of HIVAIDS dementia complexSpectrum of HIVTreatment of HIVPersistent handViral suppressionNeurologic manifestationsAsymptomatic diseaseHIV infectionNeurologic abnormalitiesNeurocognitive disordersNeurologic diseaseNeurocognitive dysfunctionTherapeutic modalitiesNervous systemHIVSevere impairmentTherapyDiseasePatientsDysfunctionPathophysiology
2013
HIV and Neurocognitive Dysfunction
Spudich S. HIV and Neurocognitive Dysfunction. Current HIV/AIDS Reports 2013, 10: 235-243. PMID: 23860944, PMCID: PMC3732773, DOI: 10.1007/s11904-013-0171-y.Peer-Reviewed Original ResearchConceptsIrreversible CNS injuryEffective antiretroviral therapySpectrum of HIVQuality of lifeEffect of treatmentCommunity of patientsAntiretroviral therapyCNS infectionNeurologic injuryHIV infectionProgressive injuryImmune activationCNS injuryCognitive dysfunctionNeurocognitive disordersNeurocognitive dysfunctionHIVCognitive impairmentViral replicationInjuryBeneficial reductionDysfunctionInfectionDisordersPatientsNeurologic complications of HIV infection: highlights from the 2013 Conference on Retroviruses and Opportunistic Infections.
Spudich SS, Ances BM. Neurologic complications of HIV infection: highlights from the 2013 Conference on Retroviruses and Opportunistic Infections. Topics In Antiviral Medicine 2013, 21: 100-8. PMID: 23981597, PMCID: PMC6148875.Peer-Reviewed Original ResearchConceptsHIV infectionOpportunistic infectionsNeurologic complicationsPathogenesis of HANDBiomarkers of HANDHIV encephalitisHIV diseaseHIV reservoirNeurologic presentationAntiretroviral adherenceHIV treatmentChronic diseasesHIV epidemicTreatment strategiesNeurocognitive disordersSevere formMild formInfectionCognitive functionComplicationsHIVPatientsDiseaseDisordersComplex conditions
2007
Immune Activation of the Central Nervous System Is Still Present after >4 Years of Effective Highly Active Antiretroviral Therapy
Edén A, Price RW, Spudich S, Fuchs D, Hagberg L, Gisslén M. Immune Activation of the Central Nervous System Is Still Present after >4 Years of Effective Highly Active Antiretroviral Therapy. The Journal Of Infectious Diseases 2007, 196: 1779-1783. PMID: 18190258, DOI: 10.1086/523648.Peer-Reviewed Original ResearchConceptsHIV RNA levelsCopies/mLActive antiretroviral therapyIntrathecal immunoactivationNeopterin levelsCerebrospinal fluidIgG indexAntiretroviral therapyPlasma HIV RNA levelsMacrophage/microglia activationHuman immunodeficiency virus (HIV) RNAUpper normal reference valueIntrathecal immunoglobulin productionYears of treatmentCentral nervous systemNormal reference valuesMicroglia activationImmune activationImmunoglobulin productionEffective treatmentCSF samplesPatientsNervous systemCell countHAART
2006
Defining and Evaluating HIV-Related Neurodegenerative Disease and Its Treatment Targets: A Combinatorial Approach to Use of Cerebrospinal Fluid Molecular Biomarkers
Gisslen M, Hagberg L, Rosengren L, Brew BJ, Cinque P, Spudich S, Price RW. Defining and Evaluating HIV-Related Neurodegenerative Disease and Its Treatment Targets: A Combinatorial Approach to Use of Cerebrospinal Fluid Molecular Biomarkers. Journal Of Neuroimmune Pharmacology 2006, 2: 112-119. PMID: 18040834, DOI: 10.1007/s11481-006-9035-1.Peer-Reviewed Original ResearchConceptsCNS HIV infectionAIDS dementia complexHIV infectionBrain injuryTreatment targetsCentral nervous system infectionNeurodegenerative diseasesSystemic HIV infectionComorbidities of patientsNervous system infectionAdjuvant treatment approachesCerebrospinal fluid markersRational trial designIntrathecal immunoactivationSystem infectionDementia complexAvailable treatmentsClinical trialsFluid markersTrial designTreatment approachesClinical practiceExperimental therapeuticsPatientsInfectionPrevalence of CXCR4 Tropism among Antiretroviral-Treated HIV-1–Infected Patients with Detectable Viremia
Hunt PW, Harrigan PR, Huang W, Bates M, Williamson DW, McCune JM, Price RW, Spudich SS, Lampiris H, Hoh R, Leigler T, Martin JN, Deeks SG. Prevalence of CXCR4 Tropism among Antiretroviral-Treated HIV-1–Infected Patients with Detectable Viremia. The Journal Of Infectious Diseases 2006, 194: 926-930. PMID: 16960780, DOI: 10.1086/507312.Peer-Reviewed Original ResearchConceptsT-cell countsX4-tropic virusesCXCR4-tropic virusesDetectable viremiaCell countUntreated human immunodeficiency virusHIV-1-infected patientsClinic-based cohortTreatment-naive participantsT-cell depletionHuman immunodeficiency virusViral coreceptor usageCXCR4 tropismSalvage therapySignificant CD4Advanced immunodeficiencyImmunodeficiency virusCell depletionCoreceptor usageCCR5 inhibitorsLow pretreatmentViremiaCD4VirusPatients